Hyphens Pharma International Ltd. (SG:1J5) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hyphens Pharma International Ltd., a leading Singapore-based pharmaceutical and consumer healthcare group, has secured exclusive rights to commercialize a new once-daily oral shingles medication, Amenalief®, across ASEAN countries. Amenalief®, recognized globally by its generic name amenamevir, offers a more convenient dosing schedule compared to other treatments that require multiple doses throughout the day. This licensing agreement with Maruho Co., Ltd. marks a significant step in expanding Hyphens Pharma’s specialty pharmaceutical portfolio.
For further insights into SG:1J5 stock, check out TipRanks’ Stock Analysis page.